Nipro Corporation (NPRRF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 16.69 means the share price is 16.69 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.62B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNipro Corporation (NPRRF) trades at $9.96. Nipro Corporation (NPRRF) is a diversified global enterprise specializing in medical devices, pharmaceuticals, and pharmaceutical packaging. Market cap: $1.62B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for NPRRF: NPRRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NPRRF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
NPRRF: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Nipro Corporation (NPRRF) Healthcare & Pipeline Overview
Nipro Corporation is a leading global provider in the healthcare sector, focusing on medical devices, pharmaceuticals, and packaging solutions, with a strong emphasis on innovation and comprehensive service delivery across diverse markets.
What Is the Investment Thesis for NPRRF?
With a market capitalization of $1.62B and a P/E ratio of 16.69, the company demonstrates solid financial health. The medical devices sector is projected to grow significantly, driven by increasing global healthcare demands and technological advancements. Nipro's focus on innovative products, such as dialysis equipment and combination pharmaceuticals, positions it well to capture market share. The company's profit margin of 2.0% and gross margin of 31.5% reflect operational efficiency, while its dividend yield of 1.72% offers additional value to investors. However, the risks associated with trading on the OTC market, including liquidity concerns and regulatory scrutiny, warrant careful consideration.
Based on FMP financials and quantitative analysis
NPRRF Key Highlights
Market Cap of $1.62B indicates a significant presence in the healthcare sector.
- P/E ratio of 16.69 suggests a competitive valuation relative to industry peers.
- Gross margin of 31.5% reflects strong operational efficiency in product manufacturing.
- Profit margin of 2.0% indicates a stable, albeit modest, profitability level.
- Dividend yield of 1.72% provides a steady income stream for investors.
Who Are NPRRF's Competitors?
NPRRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BDX Becton, Dickinson and Company | $176.42 | -1.88% | $48.6B | 705-pillar |
| MDT Medtronic plc | $91.62 | -0.29% | $117B | 795-pillar |
| SYK Stryker Corporation | $268.65 | -0.50% | $103B | 775-pillar |
| ABBV AbbVie Inc. | $254.98 | +1.62% | $451B | 765-pillar |
| JNJ Johnson & Johnson | $266.59 | +0.09% | $642B | 895-pillar |
| BLFS BioLife Solutions, Inc. | $34.92 | -0.03% | $1.71B | 905-pillar |
| NVCR Novocure | $15.35 | -1.79% | $1.79B | 305-pillar |
| LMAT LeMaitre Vascular, Inc. | $79.10 | +0.38% | $1.81B | 905-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NPRRF's Key Strengths?
Established global presence with a strong brand reputation.
- Diverse product offerings across medical devices and pharmaceuticals.
- Robust operational capabilities and logistics network.
What Are NPRRF's Weaknesses?
Dependence on the healthcare sector, which is subject to regulatory changes.
- Relatively low profit margin compared to industry leaders.
- Limited brand recognition in certain international markets.
What Could Drive NPRRF Stock Higher?
Expansion into emerging markets in Asia and Latin America to increase market share.
- Development of innovative medical devices and pharmaceuticals to meet evolving healthcare needs.
- Strategic partnerships to enhance product offerings and distribution capabilities.
What Are the Key Risks for NPRRF?
Regulatory changes impacting product approvals and market access.
- Intense competition from established players in the healthcare sector.
- Economic downturns affecting healthcare spending.
What Are the Growth Opportunities for NPRRF?
- Nipro's established product line in dialysis equipment positions it well to capture a larger market share, particularly in regions with increasing healthcare access.
- Innovative Pharmaceutical Solutions: Nipro's focus on developing combination products, such as pre-filled syringes and dual chamber bags, aligns with the growing demand for efficient drug delivery systems. The pharmaceutical market is expected to grow at a CAGR of 5.8% through 2027, providing Nipro with ample opportunities for expansion.
- Geographic Expansion in Emerging Markets: Nipro aims to penetrate emerging markets in Asia and Latin America, where healthcare infrastructure is rapidly developing. This strategic focus could significantly increase revenue streams, leveraging Nipro's existing capabilities in production and distribution.
- Growth in Pharmaceutical Packaging: The pharmaceutical packaging market is projected to reach $200 billion by 2026, driven by the need for secure and compliant packaging solutions. Nipro's comprehensive portfolio in this segment positions it to benefit from increased demand for innovative packaging solutions.
- Development of Thermostable Enzymes: Nipro's production of thermostable enzymes for clinical chemistry applications taps into a niche but growing market. As diagnostic testing becomes more prevalent, the demand for reliable and stable enzymes is expected to rise, providing Nipro with a unique growth avenue.
What Opportunities Does NPRRF Have?
- Growing demand for innovative medical devices and pharmaceuticals.
- Expansion into emerging markets with increasing healthcare needs.
- Potential for strategic partnerships to enhance product offerings.
What Are NPRRF's Competitive Advantages?
- Strong brand reputation built over decades in the healthcare industry.
- Diverse product portfolio that reduces dependence on a single revenue stream.
- Established global distribution network enhancing market reach.
- Commitment to innovation and quality, ensuring competitive advantage.
- Robust logistics and manufacturing capabilities supporting operational efficiency.
What Does NPRRF Do?
Nipro Corporation, founded in 1947 in Osaka, Japan, has evolved into a diversified global enterprise with a focus on three primary sectors: medical devices, pharmaceuticals, and pharmaceutical packaging. The company’s Medical Device division is pivotal in developing, producing, and distributing essential healthcare equipment, including products for injection-infusion therapies, dialysis treatments, and solutions for diabetes management. Nipro's Pharmaceutical segment offers innovative combination products such as dual chamber bags and pre-filled syringes, alongside contract manufacturing services for various drug forms. The Pharma Packaging division specializes in a comprehensive range of pharmaceutical containers, including glass vials, ampoules, syringes, and cartridges, which are critical for maintaining drug integrity. Additionally, Nipro manufactures thermostable enzymes for clinical chemistry applications through its 'Other business' unit. With a workforce of over 36,000 employees, Nipro Corporation has established a significant international presence, serving markets across Japan, the Americas, Europe, and Asia. The company is committed to enhancing healthcare solutions through innovation and robust distribution capabilities, positioning itself as a reliable partner in the healthcare industry.
What Products and Services Does NPRRF Offer?
- Develops and manufactures medical devices for various healthcare applications.
- Provides pharmaceuticals, including innovative combination products.
- Offers comprehensive contract manufacturing services for drug delivery systems.
- Supplies a wide range of pharmaceutical packaging solutions.
- Produces thermostable enzymes for clinical chemistry applications.
- Delivers business management services to enhance operational efficiency.
How Does NPRRF Make Money?
- Generates revenue through the sale of medical devices and pharmaceuticals.
- Offers contract manufacturing services to pharmaceutical companies.
- Provides pharmaceutical packaging solutions to ensure drug integrity.
- Manufactures specialized enzymes for clinical applications.
- Delivers business management services to optimize client operations.
What Industry Does NPRRF Operate In?
The medical instruments and supplies industry is experiencing robust growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Nipro Corporation operates within this dynamic landscape, competing against established players in the medical device and pharmaceutical sectors. As healthcare spending continues to rise, Nipro's diversified portfolio positions it favorably against competitors, enabling it to capitalize on emerging trends and consumer demands.
Who Are NPRRF's Key Customers?
- Hospitals and healthcare providers requiring medical devices.
- Pharmaceutical companies seeking contract manufacturing services.
- Research institutions needing specialized enzymes for clinical applications.
- Distributors of medical supplies and pharmaceutical products.
- Patients requiring diabetes management and dialysis solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
Nipro Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Osaka, JP. The company is led by CEO Yoshihiko Sano. NPRRF has traded publicly since 2018.
Earnings Track Record
Nipro Corporation has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 12.8% above estimates on average.
Key Financial Metrics
Return on equity for Nipro Corporation stands at 5.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.1%, showing how much profit it generates from its asset base. NPRRF trades at a trailing price-to-earnings ratio of 16.69, below the Healthcare sector average of ~21.50x. A current ratio of 1.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.4%, the inverse of the P/E and a quick read on earnings relative to price.
NPRRF Valuation & Market Position
With a $1.62B market cap, Nipro Corporation sits in the small-cap segment of the market.
NPRRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established global presence with a strong brand reputation.
- Diverse product offerings across medical devices and pharmaceuticals.
- Robust operational capabilities and logistics network.
- Upcoming: Expansion into emerging markets in Asia and Latin America to increase market share.
Bear Case
- Dependence on the healthcare sector, which is subject to regulatory changes.
- Relatively low profit margin compared to industry leaders.
- Limited brand recognition in certain international markets.
- Potential: Regulatory changes impacting product approvals and market access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
NPRRF Latest News
-
STEMIRAC Clinical, Regulatory and Commercial Intelligence Report 2026: Highlights Growth Opportunities in Spinal Cord Injury Treatment
Yahoo! Finance: NPRRF News · Sep 9, 2026
-
Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA
Yahoo! Finance: NPRRF News · Sep 7, 2026
NPRRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NPRRF.
Price Targets
Wall Street price target analysis for NPRRF.
NPRRF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NPRRF; grades run from A+ (80-100) to F (below 30).
Latest News
STEMIRAC Clinical, Regulatory and Commercial Intelligence Report 2026: Highlights Growth Opportunities in Spinal Cord Injury Treatment
Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA
Leadership: Yoshihiko Sano
CEO
Yoshihiko Sano has been instrumental in leading Nipro Corporation since its inception. With a background in engineering and extensive experience in the medical device industry, he has played a key role in driving the company's strategic vision. Sano has a strong track record of fostering innovation and expanding Nipro's global footprint, particularly in the Asian and American markets.
Track Record: Under Sano's leadership, Nipro has achieved significant growth in its product offerings and market presence. His strategic decisions have led to successful expansions in emerging markets and a focus on innovative healthcare solutions.
NPRRF OTC Market Information
Nipro Corporation trades on the OTC Other tier, which generally includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier can indicate a higher risk profile, as it often involves less stringent reporting and regulatory oversight.
- OTC Tier: OTC Other
- Limited regulatory oversight compared to stocks listed on major exchanges.
- Potential for lower trading volumes, impacting liquidity.
- Higher volatility and price fluctuations common in OTC markets.
- Review Nipro's latest financial statements and disclosures.
- Assess the company's market position and competitive landscape.
- Monitor news related to regulatory changes in the healthcare sector.
- Evaluate the company's growth strategies and product pipeline.
- Verify the availability of analyst coverage and market sentiment.
- Established history since 1947 in the healthcare industry.
- Diverse product portfolio and global market presence.
- Strong management team with a track record of growth.
Common Questions About NPRRF (Healthcare)
Is NPRRF a good stock?
Stock Expert AI does not rate NPRRF buy, sell or hold. Nipro Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What revenue streams does Nipro Corporation have in healthcare?
Nipro Corporation generates revenue through multiple streams, including the sale of medical devices, pharmaceuticals, and contract manufacturing services. The company also earns income from its pharmaceutical packaging solutions and specialized enzyme production, allowing it to diversify its revenue base and reduce dependency on any single product line.
What are the key factors to evaluate for NPRRF?
Evaluate NPRRF on fundamentals, analyst consensus, and risk factors. P/E: 16.69x vs the S&P 500's ~20-25x. With a market capitalization of $1.62B and a P/E ratio of 16.69, the company demonstrates solid financial health. Not financial advice.
How frequently does NPRRF data refresh on this page?
NPRRF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NPRRF's recent stock price performance?
Nipro Corporation (NPRRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established global presence with a strong brand reputation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NPRRF overvalued or undervalued right now?
Nipro Corporation (NPRRF) trades at 16.69x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of NPRRF?
Yes, most major brokerages offer fractional shares of Nipro Corporation (NPRRF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NPRRF's earnings and financial reports?
Nipro Corporation (NPRRF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for NPRRF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.